262 related articles for article (PubMed ID: 33715009)
21. Structural insights into IL-6 signaling inhibition by therapeutic antibodies.
Wang M; Chen L; He J; Xia W; Ye Z; She J
Cell Rep; 2024 Mar; 43(3):113819. PubMed ID: 38393945
[TBL] [Abstract][Full Text] [Related]
22. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
Kozma GT; Mészáros T; Bakos T; Hennies M; Bencze D; Uzonyi B; Győrffy B; Cedrone E; Dobrovolskaia MA; Józsi M; Szebeni J
Front Immunol; 2021; 12():642860. PubMed ID: 33995361
[TBL] [Abstract][Full Text] [Related]
23. IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19.
Kishimoto T; Kang S
Annu Rev Immunol; 2022 Apr; 40():323-348. PubMed ID: 35113729
[TBL] [Abstract][Full Text] [Related]
24. Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review.
Roshanravan N; Seif F; Ostadrahimi A; Pouraghaei M; Ghaffari S
Arch Med Res; 2020 Oct; 51(7):608-612. PubMed ID: 32682575
[TBL] [Abstract][Full Text] [Related]
25. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
26. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
27. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
[TBL] [Abstract][Full Text] [Related]
28. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Du P; Geng J; Wang F; Chen X; Huang Z; Wang Y
Int J Med Sci; 2021; 18(6):1356-1362. PubMed ID: 33628091
[TBL] [Abstract][Full Text] [Related]
29. Are all cytokine storms the same?
Panoskaltsis N
Cancer Immunol Immunother; 2021 Apr; 70(4):887-892. PubMed ID: 33416946
[TBL] [Abstract][Full Text] [Related]
30. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Xia L; Yuan LZ; Hu YH; Liu JY; Hu GS; Qi RY; Zhang TY; Xiong HL; Zheng ZZ; Lin HW; Zhang JM; Yu C; Zhou M; Ma J; Cheng T; Chen RR; Guan Y; Xia NS; Liu W
Cell Mol Immunol; 2023 Apr; 20(4):351-364. PubMed ID: 36864189
[TBL] [Abstract][Full Text] [Related]
31. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?
Morris G; Bortolasci CC; Puri BK; Marx W; O'Neil A; Athan E; Walder K; Berk M; Olive L; Carvalho AF; Maes M
Cytokine; 2021 Aug; 144():155593. PubMed ID: 34074585
[TBL] [Abstract][Full Text] [Related]
32. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
33. T cell immunobiology and cytokine storm of COVID-19.
Luo XH; Zhu Y; Mao J; Du RC
Scand J Immunol; 2021 Mar; 93(3):e12989. PubMed ID: 33113222
[TBL] [Abstract][Full Text] [Related]
34. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
35. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.
Zhou Z; Price CC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1407-1412. PubMed ID: 33094669
[TBL] [Abstract][Full Text] [Related]
36. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
Pinheiro MM; Fabbri A; Infante M
Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 in patients with cancer: Risks and precautions.
Razavi A; Hamblin MR; Rezaei N
Am J Emerg Med; 2021 Oct; 48():357-360. PubMed ID: 33546958
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date.
Si S; Teachey DT
Ther Clin Risk Manag; 2020; 16():705-714. PubMed ID: 32801727
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
